A randomized, double blind, two-arms placebo-controlled, parallel group, multicenter study of rimonabant 20 mg once daily in the treatment of atherogenic dyslipidemia in abdominally obese patients

• Conditions: Abdominally obese patients with atherogenic dyslipidemia; MedDRA version: 6.1Level: HLTClassification code 10014486

• Registration Number: EUCTR2005-000807-33-IT
• Lead Sponsor: SANOFI-SYNTHELABO

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2006-03-23
• Last Update Posted: 19 March 2012

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 740

Inclusion Criteria

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Not provided

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified